

**DRUG DISCOVERY TODAY****Editorial**

**Editor:** Steve Carney  
**Content Development Manager:** Pien van Spijker  
**Journal Manager:** Bharathi Sims  
**Publisher:** Fernanda Ogochi  
**Editorial Enquiries:**  
*Drug Discovery Today*  
 Elsevier  
 125 London Wall, London, EC2Y 5AS, UK  
 Tel: +44 (0) 20 8439 5525  
 Fax: +44 (0)1865 853067  
 Email: ddt@drugdiscoverytoday.com

**ADVISORY EDITORIAL BOARD**

**Jürgen Bajorath** *University of Bonn, Germany*  
**Walter Blackstock** *Experimental Therapeutics Centre, Singapore*  
**David Brayden** *University College Dublin, Ireland*  
**Paul Caron** *Integrated Profiling, USA*  
**David Cavalla** *Numedicus Ltd., UK*  
**David Clark** *Argenta Discovery, UK*  
**Dalia Cohen** *ALN Associates, USA*  
**Donald Daley** *Argenta Discovery, UK*  
**Sean Ekins** *Collaborations in Chemistry, USA*  
**Hans-Peter Fischer** *GeneData, Switzerland*  
**Peter Ghazal** *University of Edinburgh, UK*  
**Christopher M. Hill** *Merck, USA*  
**Nick Hird** *Takeda Chemical Industries, Japan*  
**Enoch Huang** *Pfizer, USA*  
**Thomas Joos** *University of Tuebingen, Germany*  
**Vincent H.L. Lee** *Chinese University of Hong Kong, China*  
**David Lewin** *Yale University, USA*  
**Christopher A. Lipinski** *Melior Discovery, USA*  
**Lorenz Mayr** *AstraZeneca, UK*  
**Nick Meanwell** *Bristol-Myers Squibb, USA*  
**BK Muralidhara** *Acceleron Pharma Inc, USA*  
**Mark Murcko** *Disruptive Biomedical, LLC, USA*  
**Fajun Nan** *Shanghai Institute of Materia Medica, China*  
**Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge*  
**Gitte Neubauer** *Cellzome, Germany*  
**Eric Neumann** *Clinical Semantics Group Consulting, USA*  
**Tim Peakman** *UK Biobank, UK*  
**Norton Peet** *Microbiotix, Inc., USA*  
**Manuel Peitsch** *Swiss Institute of Bioinformatics, Switzerland*  
**Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA*  
**Janice Reichert** *Reichert Biotechnology Consulting LLC, MA, USA*  
**John Reidhaar-Olson** *Albert Einstein College of Medicine, New York, USA*  
**Mike Romanos** *Crescendo Biologics, Cambridge, UK*  
**Raymond C. Rowe** *Intelligensys, UK*  
**Andreas Russ** *University of Oxford, UK*  
**Esther Schmid** *EFS Strategy and Business Consulting, UK*  
**Jonathan Sheldon** *Translational Medicine, Oracle, UK*  
**Michael Snyder** *Stanford University, USA*  
**Susie Stephens** *Johnson & Johnson, USA*  
**Robert Strausberg** *Ludwig Institute for Cancer Research, New York, USA*  
**Yuichi Sugiyama** *University of Tokyo, Japan*  
**David Szymkowski** *Xencor, USA*  
**Nick Terrett** *Ensemble Discovery, USA*  
**Vladimir Torchilin** *Northeastern University, Boston, USA*  
**Mark Whittaker** *Evotec OAI, UK*  
**Hans Winkler** *Janssen Pharmaceutica, Belgium*  
**Limsoon Wong** *National University of Singapore*  
**X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

# DRUG DISCOVERY TODAY

## REVIEWS (continued)

- 2315 Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics**  
*Md. Asaduzzaman Khan, Mousumi Tania and Junjiang Fu*
- 2323 DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs**  
*Jie Yu, Tianli Xie, Zhe Wang, Xuwen Wang, Su Zeng, Yu Kang and Tingjun Hou*
- 2332 Allosteric inhibition of HIF-2 as a novel therapy for clear cell renal cell carcinoma**  
*Yancheng Yu, Quanwei Yu and Xiaojin Zhang*
- 2341 The NCATS Pharmaceutical Collection: a 10-year update**  
*Ruili Huang, Hu Zhu, Paul Shinn, Deborah Ngan, Lin Ye, Ashish Thakur, Gurmit Grewal, Tongan Zhao, Noel Southall, Mathew D. Hall, Anton Simeonov and Christopher P. Austin*

### FORTHCOMING ARTICLES:

**Chemometrics: a complementary tool to guide the isolation of pharmacologically active natural products.**

*By Axhell A. Cornejo-Báez, Luis M. Peña-Rodríguez, Radames Alvarez-Zapata, Maribel Vazquez-Hernández and Alberto Sánchez-Medina.*

**Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic.**

*By Sung In Lim*

**Drug-induced liver injury severity and toxicity (DILIST): binary classification of 1303 drugs by human hepatotoxicity.**

*By Shraddha Thakkar, Ting Li, Zhichao Liu, Leihong Wu, Ruth Roberts and Weida Tong.*

**Allosteric inhibition of HIF-2 as a novel therapy for clear cell renal cell carcinoma.**

*By Yancheng Yu, Quanwei Yu and Xiaojin Zhang.*